Loading...
 
Mediterr J Rheumatol 2019;30(3):167-70
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
Authors Information

2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens Medical School, Hippokration General Hospital, Athens, Greece

References
  1. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol (Hoboken, NJ) 2015;68(1):1-26. [https://doi.org/10.1002/acr.22783] [PMID: 26545825]
  2. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76(6):960-77. [https://doi.org/10.1136/annrheumdis-2016-210715] [PMID: 28264816]
  3. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 2017;76(7):1253-62. [https://doi.org/10.1136/annrheumdis-2016-210457] [PMID: 28143815] [PMCID: PMC5530353]
  4. Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 2018;77(5):644-9. [https://doi.org/10.1136/annrheumdis-2017-211796] [PMID: 29092853] [PMCID: PMC5909751]
  5. Winthrop KL, Baddley JW. Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question. Ann Rheum Dis 2018;77(5):631-3. [https://doi.org/10.1136/annrheumdis-2017-212588] [PMID: 29459427]
  6. Mori S, Sugimoto M. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford) 2012;51(12):2120-30. [https://doi.org/10.1093/rheumatology/kes244] [PMID: 23001613] [PMCID: PMC3510430]
  7. Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology 2019;58(Supplement_1):i34-i42. [https://doi.org/10.1093/rheumatology/key287] [PMID: 30806708] [PMCID: PMC6390880]
  8. Cohen S, Curtis JR, DeMasi R, Chen Y, Fan H, Soonasra A, et al. Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis. Rheumatol Ther 2018;5(1):283-91. [https://doi.org/10.1007/s40744-018-0097-3] [PMID: 29470834] [PMCID: PMC5935628]
  9. Mimori T, Harigai M, Atsumi T, Kuwana M, Takei S, Tamura N, et al. Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data [abstract]. Arthritis Rheumatol 2017:69(suppl 10). https://acrabstracts.org/abstract/post-marketing-surveillance-of-tofacitinib-in-japanese-patients-with-rheumatoid-arthritis-an-interim-report-of-safety-data/
  10. Sandborn WJ, Panés J, D’Haens GR, Sands BE, Su C, Moscariello M, et al. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol 2019;17(8):1541-50. [https://doi.org/10.1016/j.cgh.2018.11.035] [PMID: 30476584]
  11. Winthrop K, Lindsey S, Harigai M, Bradley JD, Chen L, Hyslop DL, et al. Tuberculosis, Potential Opportunistic Infections, and Other Infections of Interest in Patients with Moderate to Severe Rheumatoid Arthritis in the Baricitinib Program [abstract]. Arthritis Rheumatol 2017;69(suppl 10). https://acrabstracts.org/abstract/tuberculosis-potential-opportunistic-infections-and-other-infections-of-interest-in-patients-with-moderate-to-severe-rheumatoid-arthritis-in-the-baricitinib-program/
  12. Pirker IFJ, Krane-Nuber J, Albrich WC, Müller R, Neumann T. Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation. BMC Rheumatol 2018;2(1):34. [https://doi.org/10.1186/s41927-018-0042-7] [PMID: 30886984] [PMCID: PMC6390573]
  13. Doyle L, Vogel S, Procop GW. Pneumocystis PCR: It Is Time to Make PCR the Test of Choice. Open Forum Infect Dis 2017;4(4). [https://doi.org/10.1093/ofid/ofx193] [PMID: 29062861] [PMCID: PMC5641380]
  14. Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016;71(9):2386-96. [https://doi.org/10.1093/jac/dkw156] [PMID: 27550991]
  15. Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother 2016;71(9):2405-13. [https://doi.org/10.1093/jac/dkw158] [PMID: 27550993]
  16. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis Pneumonia in Immunocompromised Non-HIV-Infected Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials. Mayo Clin Proc 2007;82(9):1052-9. [https://doi.org/10.4065/82.9.1052] [PMID: 17803871]
  17. Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Stern A, ed. Cochrane database Syst Rev 2014;(10):CD005590. [https://doi.org/10.1002/14651858.CD005590.pub3] [PMID: 25269391] [PMCID: PMC6457644]
  18. Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994;21(2):246-51. [PMID: 8182632]